Helius Medical announces establishment of Revelation Neuro subsidiary

Helius Medical (HSDT) Technologies announced the establishment of Revelation Neuro, its wholly-owned private subsidiary focused on the development of non-implantable AI powered BCI technology. “We are thrilled to establish Revelation Neuro to pursue the development of a new gold standard of care for personalized neurorehabilitation using a non-implantable AI powered BCI combining our newly developed intellectual property with Helius’ existing IP. Our technology relies on its proven ability to modulate known target brain processes and trigger therapeutic responses by using translingual stimulation without risky implantation. We believe Revelation Neuro’s BCI technology will be a unique and less invasive therapeutic option,” said Dane Andreeff, Helius President and Chief Executive Officer.